Acadia is worth more than double Neuren again despite owning the majority of Daybue, failing a Phase 3 trial in schizophrenia and noting no label extension for their only other compound that generates cashflow (Nuplazid). In that same time, we've had 3 positive Phase 2 trials, and we are about to announce more indications. The growing valuation gap is confusing given the explanations above, which should affect Acadia as well. The only late-stage asset ACAD has is in PWS hyperphagia.
ACAD 2.75B USD
NEU 1.26 USD
Share Price, page-11542
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |